453 - Frequency of Symptoms and Asymptomatic SARS-CoV-2 Infection in New Orleans, Louisiana

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Amy K. Feehan

Clinical Research Scientist
Clinical Infectious Diseases Research, Ochsner Clinic Foundation, University of Queensland
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

DF

Daniel Fort

Program Manager
Center for Outcomes and Health Services Research, Ochsner Clinic Foundation
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Julia Garcia-Diaz

Dr
Ochsner Medical Center
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EP

Eboni Price-Haywood

Sr Physician-Medical Director
Center for Outcomes and Health Services Research, Ochsner Clinic Foundation
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
CV

Cruz Velasco

Sr Biostatistician
Center for Outcomes and Health Services Research, Ochsner Clinic Foundation
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
ES

Eric Sapp

CEO
Public Democracy
Arlington, Virginia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
DP

Dawn Pevey

Sys VP-Service Lines
Ochsner Health
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
LS

Leonardo Seoane

Sr VP-Chief Academic Officer
University of Queensland, Ochsner Clinical School; Center for Outcomes and Health Services Research, Ochsner Clinic Foundation; Ochsner Health; Louisiana State University Health Science Center-Shreveport
New Orleans, Louisiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: Individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who do not report symptoms throughout the course of infection (asymptomatic) or those who are asymptomatic when they first contract the virus (presymptomatic) are a major public health concern. However, few prevalence studies to date have targeted the question of asymptomatic frequency within a community.

Methods: A stratified, random sample of subjects were sent to testing sites to complete a verbal consent, survey, nasopharyngeal swab, and blood draw. Swabs were tested for active viral shedding (PCR) and blood was tested for immunoglobulin G (IgG) specific to SARS-CoV-2.Disease progression and IgG antibody response

Results: Of the 2,640 subjects, 24 (0·9%) were PCR-positive alone, 30 (1·1%) were PCR-positive and IgG-positive, and 129 (4·9%) were IgG-positive alone. Subjects who reported anosmia were 17 times more likely to test positive. Thirty-eight percent of subjects never experienced symptoms despite developing antibodies to the virus, and 75% did not experience symptoms in the early stage of infection. Rates of reported asymptomatic infection and comorbidities statistically significantly increased with age.

Conclusion: This is the first randomized study that pairs PCR and IgG serology that addresses asymptomatic SARS-CoV-2 infection, showing a high frequency of asymptomatic disease. More research is needed to clarify differences between symptomatic and asymptomatic disease. Prevalence and outcomes studies of SARS-CoV-2 should include this group.